Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of THR-149 versus aflibercept in diabetic macular oedema
2019-001506-17Phase 2Completed
- Sponsor
- Oxurion
- Start
- Mar 2020
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of THR-149 in diabetic macular edema (DME) (2 arms), sponsored by Oxurion. Primary endpoint: Mean change in BCVA ETDRS letter score from baseline at Month 3. Started Mar 2020; status: completed.
02
Drugs
THR-149
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2019-001506-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001506-17.